Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
Linking AIM2 Inflammasome Activation, Mitochondrial Dysfunction and Chronic Inflammation in Ankylosing Spondylitis
Catalina Alina Boengiu1, Andreea-Lili Barbulescu2, Cristiana Cerasella Dragomirescu3
1Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Abstract:
The absent in melanoma 2 (AIM2) inflammasome is a cytosolic DNA sensor that links genomic instability, mitochondrial dysfunction, and chronic inflammation. Unlike the nucleotide-binding domain, leucine-rich repeat (NLR) family pyrin domain-containing protein 3 (NLRP3) inflammasome, AIM2 is activated directly by double-stranded Deoxyribonucleic Acid (dsDNA), including mitochondrial DNA (mtDNA) released under stress conditions. This positions AIM2 at the intersection of oxidative stress, impaired mitophagy, and innate immune dysregulation. Current therapies for ankylosis spondylitis (AS), such as anti-tumor necrosis factor (TNF), anti-interleukin 17 (IL-17), and Janus kinase (JAK) inhibitors, improve clinical outcomes; however, they do not address upstream mitochondrial dysfunction or DNA-driven inflammasome activation. By contrast, other inflammasomes, such as AIM2, remain comparatively less studied. Since autoimmune diseases, including AS, are frequently accompanied by uncontrolled innate immune responses to self-DNA, these findings provide a framework for comprehending the mechanisms of AIM2 activation and its interaction with inflammation, mitophagy, and oxidative stress. Here, we review the current evidence on AIM2 inflammasome involvement in AS pathogenesis and its potential as a therapeutic target. This approach offers new insight into disease control through re-establishing the balance between mitochondrial dysfunction and autoimmunity.
Insights
The absent in melanoma 2 (AIM2) inflammasome senses DNA and is implicated in ankylosis spondylitis. Targeting AIM2 may offer new therapeutic strategies by addressing mitochondrial dysfunction and autoimmunity.
Area of Science:
- Immunology
- Molecular Biology
- Genetics
Background:
- The absent in melanoma 2 (AIM2) inflammasome is a cytosolic DNA sensor activated by double-stranded DNA (dsDNA).
- AIM2 links genomic instability, mitochondrial dysfunction, and chronic inflammation, particularly in autoimmune diseases like ankylosis spondylitis (AS).
- Current AS therapies do not target upstream mitochondrial dysfunction or DNA-driven inflammasome activation.
Purpose of the Study:
- To review evidence on AIM2 inflammasome involvement in AS pathogenesis.
- To explore AIM2 as a potential therapeutic target for AS.
- To understand AIM2's interaction with inflammation, mitophagy, and oxidative stress in AS.
Main Methods:
- Literature review of current evidence on AIM2 inflammasome in AS.
- Analysis of AIM2 activation mechanisms, including dsDNA and mitochondrial DNA (mtDNA) release.
- Examination of the interplay between AIM2, oxidative stress, mitophagy, and innate immunity.
Main Results:
- AIM2 is activated by dsDNA, including mtDNA released during stress, positioning it at the nexus of oxidative stress and immune dysregulation.
- AIM2 inflammasome activation is implicated in the pathogenesis of autoimmune diseases, including AS.
- AIM2 remains less studied compared to other inflammasomes like NLRP3.
Conclusions:
- AIM2 activation is a key factor in AS pathogenesis, driven by mitochondrial dysfunction and self-DNA.
- Targeting the AIM2 inflammasome presents a novel therapeutic avenue for AS.
- Restoring balance between mitochondrial function and autoimmunity through AIM2 modulation may improve disease control.
Related Concept Videos
The JAK-STAT Signaling Pathway
Myocarditis I: Introduction
Rheumatic Heart Disease I: Introduction
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Inflammation
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

